{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:29Z","timestamp":1784546309534,"version":"3.55.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Asthma is a common and potentially serious condition affecting 300 million people worldwide. For many years, we have relied on a one-size-fits-all approach to its management, using corticosteroids and bronchodilators for all symptomatic patients. However, with more recent advances, it has become clear that asthma is a heterogeneous condition with multiple different underlying pathways. Understanding the different subtypes will be a key to giving us the ability to intervene in a targeted way to personalize care for patients with asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Sources of data<\/jats:title><jats:p>Key published literature, guidelines and trials from clinicaltrials.gov.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of agreement<\/jats:title><jats:p>The most widely studied of these subtypes is T2 high eosinophilic asthma, for which there are an increasing number of biologic therapies available. T2 high asthma is associated with the cytokines interleukin (IL)-4, IL-5 and IL-13, for each of which biologics have been developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of controversy<\/jats:title><jats:p>It is currently unclear which of the available biologics provides superior efficacy. It is also unclear how to select which biologic for which patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Growing points<\/jats:title><jats:p>Head-to-head trials of the available T2 biologics will be important to determine superiority, and a suggested order for trialling biologics. Going further than this, we would like to see further analyses of available biologics to allow us to predict responders from non-responders in advance of administering therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas timely for developing research<\/jats:title><jats:p>Non-eosinophilic T2 low asthma is an area that is under-researched and for which there are few treatments available. It is likely that there are different subtypes in this category of asthma and unravelling what these are will be crucial to developing effective treatments.<\/jats:p><\/jats:sec>","DOI":"10.1093\/bmb\/ldaa004","type":"journal-article","created":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T12:07:25Z","timestamp":1581250045000},"source":"Crossref","is-referenced-by-count":5,"title":["Targeted biologic therapy for asthma"],"prefix":"10.1093","author":[{"given":"Gareth","family":"Hynes","sequence":"first","affiliation":[{"name":"Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D","family":"Pavord","sequence":"first","affiliation":[{"name":"Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"2020042119485262200_ref1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12916-016-0657-8","article-title":"The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases","volume":"14","author":"Mukherjee","year":"2016","journal-title":"BMC Med"},{"key":"2020042119485262200_ref2","volume-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma","year":"2019"},{"key":"2020042119485262200_ref3","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"key":"2020042119485262200_ref4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Brusselle","year":"2013","journal-title":"Nat Med"},{"key":"2020042119485262200_ref6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41385-018-0049-9","article-title":"Synergistic activation of pro-inflammatory type-2 CD8(+) T lymphocytes by lipid mediators in severe eosinophilic asthma","volume":"11","author":"Hilvering","year":"2018","journal-title":"Mucosal Immunol"},{"key":"2020042119485262200_ref7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2016.08.032","article-title":"Mechanism of Th2\/Th17-predominant and neutrophilic, Th2\/Th17-low subtypes of asthma","volume":"139","author":"Liu","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.5858\/2000-124-1382-IE","article-title":"Immunoglobulin E: importance in parasitic infections and hypersensitivity responses","volume":"124","author":"Winter","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"2020042119485262200_ref9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/ajrccm.164.supplement_1.2103024","article-title":"The role of immunoglobulin E in allergy and asthma","volume":"164","author":"Platts-Mills","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM198902023200502","article-title":"Association of asthma with serum IgE levels and skin-test reactivity to allergens","volume":"320","author":"Burrows","year":"1989","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0091-6749(95)70175-3","article-title":"Relationship between serum IgE and airway responsiveness in adults with asthma","volume":"95","author":"Sunyer","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI119252","article-title":"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics","volume":"99","author":"Corne","year":"1997","journal-title":"J Clin Invest"},{"key":"2020042119485262200_ref13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"2020042119485262200_ref15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"2020042119485262200_ref16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1164\/ajrccm.157.1.9703027","article-title":"Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics","volume":"157","author":"Shi","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"2020042119485262200_ref20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1753465817717134","article-title":"Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects","volume":"11","author":"Maspero","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"2020042119485262200_ref27","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2020042119485262200_ref28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2020042119485262200_ref29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000447692","article-title":"A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma","volume":"170","author":"Bagnasco","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"2020042119485262200_ref31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MCP.0000000000000224","article-title":"Airway inflammation in asthma: key players beyond the Th2 pathway","volume":"22","author":"KleinJan","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2020042119485262200_ref32","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: central mediator of allergic asthma","volume":"282","author":"Wills-Karp","year":"1998","journal-title":"Science"},{"key":"2020042119485262200_ref33","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Grunig","year":"1998","journal-title":"Science"},{"key":"2020042119485262200_ref34","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.4049\/jimmunol.176.12.7495","article-title":"Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling","volume":"176","author":"Daines","year":"2006","journal-title":"J Immunol"},{"key":"2020042119485262200_ref35","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020042119485262200_ref36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"key":"2020042119485262200_ref38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"2020042119485262200_ref40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"2020042119485262200_ref42","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S2213-2600(16)30274-0","article-title":"Lessons from LAVOLTA","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref43","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1126\/scisignal.1.51.pe55","article-title":"Untangling the complex web of IL-4- and IL-13-mediated signaling pathways","volume":"1","author":"Wills-Karp","year":"2008","journal-title":"Sci Signal"},{"key":"2020042119485262200_ref44","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","article-title":"Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized, placebo-controlled trial","volume":"160","author":"Borish","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm.2754","article-title":"Therapies for allergic inflammation: refining strategies to induce tolerance","volume":"18","author":"Akdis","year":"2012","journal-title":"Nat Med"},{"key":"2020042119485262200_ref46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/1744666X.4.6.743","article-title":"Use of biologicals as immunotherapy in asthma and related diseases","volume":"4","author":"Walker","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"key":"2020042119485262200_ref47","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"2020042119485262200_ref49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(16)30311-7","article-title":"Dupilumab: a potential new treatment for severe asthma","volume":"388","author":"Chung","year":"2016","journal-title":"Lancet"},{"key":"2020042119485262200_ref51","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11882-996-0006-7","article-title":"Thymic stromal lymphopoietin: a potential therapeutic target for allergy and asthma","volume":"6","author":"Huston","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"2020042119485262200_ref52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2017.03.032","article-title":"Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin","volume":"141","author":"Liu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref53","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref54","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"2020042119485262200_ref55","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1067\/mai.2001.117929","article-title":"IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines","volume":"108","author":"Molet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-7-135","article-title":"IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?","volume":"7","author":"Bullens","year":"2006","journal-title":"Respir Res"},{"key":"2020042119485262200_ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ACI.0000000000000227","article-title":"Th17 regulating lower airway disease","volume":"16","author":"Cosmi","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2020042119485262200_ref58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"AmJRespirCrit Care Med"},{"key":"2020042119485262200_ref60","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.200902-0166OC","article-title":"The prevalence of nonadherence in difficult asthma","volume":"180","author":"Gamble","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref61","doi-asserted-by":"crossref","first-page":"A151","DOI":"10.1136\/thx.2010.151043.25","article-title":"P174\u00a0identifying non-adherence with asthma medication and the relationship to clinical outcomes amongst adults with difficult-to-control asthma","volume":"65","author":"Murphy","year":"2010","journal-title":"Thorax"},{"key":"2020042119485262200_ref62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J Asthma"},{"key":"2020042119485262200_ref63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref64","doi-asserted-by":"crossref","first-page":"5698212","DOI":"10.1155\/2018\/5698212","article-title":"Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","volume":"2018","author":"Bagnasco","year":"2018","journal-title":"Biomed Res Int"},{"key":"2020042119485262200_ref65","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2017.11.026","article-title":"Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma","volume":"6","author":"Gunsoy","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020042119485262200_ref66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2020042119485262200_ref67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"2020042119485262200_ref68","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref69","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 Sinus-24 study","volume":"143","author":"Han","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2020042119485262200_ref70","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref72","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref73","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2020042119485262200_ref74","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042119485262200_ref75","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/advance-article-pdf\/doi\/10.1093\/bmb\/ldaa004\/33106021\/ldaa004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bmb\/advance-article-pdf\/doi\/10.1093\/bmb\/ldaa004\/33106021\/ldaa004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T18:10:21Z","timestamp":1614363021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/advance-article\/doi\/10.1093\/bmb\/ldaa004\/5822936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldaa004","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"value":"0007-1420","type":"print"},{"value":"1471-8391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"article-number":"ldaa004"}}